AUTHOR=Specchia Giorgina , Pregno Patrizia , Breccia Massimo , Castagnetti Fausto , Monagheddu Chiara , Bonifacio Massimiliano , Tiribelli Mario , Stagno Fabio , Caocci Giovanni , Martino Bruno , Luciano Luigiana , Pizzuti Michele , Gozzini Antonella , Scortechini Anna Rita , Albano Francesco , Bergamaschi Micaela , Capodanno Isabella , Patriarca Andrea , Fava Carmen , Rege-Cambrin Giovanna , Sorà Federica , Galimberti Sara , Bocchia Monica , Binotto Gianni , Reddiconto Giovanni , DiTonno Paolo , Maggi Alessandro , Sanpaolo Grazia , De Candia Maria Stella , Giai Valentina , Abruzzese Elisabetta , Miggiano Maria Cristina , La Barba Gaetano , Pietrantuono Giuseppe , Guella Anna , Levato Luciano , Mulas Olga , Saccona Fabio , Rosti Gianantonio , Musto Pellegrino , Di Raimondo Francesco , Pane Fabrizio , Baccarani Michele , Saglio Giuseppe , Ciccone Giovannino TITLE=Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network JOURNAL=Frontiers in Oncology VOLUME=11 YEAR=2021 URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.739171 DOI=10.3389/fonc.2021.739171 ISSN=2234-943X ABSTRACT=

An observational prospective study was conducted by the CML Italian network to analyze the role of baseline patient characteristics and first line treatments on overall survival and CML-related mortality in 1206 newly diagnosed CML patients, 608 treated with imatinib (IMA) and 598 with 2nd generation tyrosine kinase inhibitors (2GTKI). IMA-treated patients were much older (median age 69 years, IQR 58-77) than the 2GTKI group (52, IQR 41-63) and had more comorbidities. Estimated 4-year overall survival of the entire cohort was 89% (95%CI 85.9-91.4). Overall, 73 patients (6.1%) died: 17 (2.8%) in the 2GTKI vs 56 (9.2%) in the IMA cohort (adjusted HR=0.50; 95% CI=0.26-0.94), but no differences were detected for CML-related mortality (10 (1.7%) vs 11 (1.8%) in the 2GTKIs vs IMA cohort (sHR=1.61; 0.52-4.96). The ELTS score was associated to CML mortality (high risk vs low, HR=9.67; 95%CI 2.94-31.74; p<0.001), while age (per year, HR=1.03; 95%CI 1.00-1.06; p=0.064), CCI (4-5 vs 2, HR=5.22; 95%CI 2.56-10.65; p<0.001), ELTS score (high risk vs low, HR=3.11; 95%CI 1.52-6.35, p=0.002) and 2GTKI vs IMA (HR=0.26; 95%CI 0.10-0.65, p=0.004) were associated to an increased risk of non-related CML mortality. The ELTS score showed a better discriminant ability than the Sokal score in all comparisons.